Yurong Lai

Dr. Lai is Executive Director of Drug Metabolism at Gilead Sciences. His current role in Gilead is to manage DM-drug disposition labs, to implement in vitro/in vivo preclinical/clinical strategies for compound advancement to the market and product life-cycle management. Dr Lai is a Fellow of American Association of Pharmaceutical Scientists (AAPS) and holds an Adjunct Faculty position in the Department of Pharmacy of the University of Rhode Island. He received his M.D from Fujian Medical University in China and his Ph.D. (Toxicology) from Sapporo Medical University in Japan in 1998. From 1998 to 2001, he was a research fellow of Japanese Society for Promotion (JSPS) in Department of Physiopathology, Graduate School of Medicine of Hokkaido University, followed by a position as Research Associate in Department of Pharmaceutics, University of Washington. In 2004, he Joined pharmacokinetics, dynamics and metabolism (PDM), PGRD St. Louis and then moved to Groton in 2010, Pfizer Inc. and has been serving as a PDM representative (PI), postdoc supervisor and lab head for drug transporter research. In 2013, he joined BMS. He has been a research fellow and had a significant role in translational researches in transporter associated ADME-PK-Tox. In 2017, he moved to Gilead Science. He is a patent inventor and the author of a book, book chapters and over 130 original publications in the peer-reviewed journal. He is associate editor/editorial board member of top ranking DMPK journals including Frontier Pharmacology, DMD, BDD, JPS etc.